Prevalence and Risk Factors of Fatty Liver Disease in Psoriasis: A systematic Review and Meta-analysis Based on NAFLD/MAFLD Diagnostic Criteria
Description
This is supplementary data on the prevalence of comorbidities between psoriasis and fatty liver disease from a meta-analysis.Our meta-analysis fills this gap by analyzing heterogeneity across various subgroups to identify factors associated with higher co-prevalence and provide updated evidence.We searched the PubMed, Embase, Cochrane Library, and Web of Science databases from inception through July 2025，eligible trials included observational studies reporting NAFLD/MAFLD prevalence in psoriasis patients. Psoriasis diagnosis had to be standardized, and NAFLD/MAFLD diagnosis required clear criteria. Controls were non-psoriasis patients (Supplementary Figure S1). A random-effects model determined pooled prevalence and 95% Confidence Intervals with R software. Meta-regression based on study-level aggregate data were performed to assess the potential influence of study-level characteristics on the estimated prevalence and odds ratios. Subgroup analyses were performed for variables that were either statistically significant in meta-regression or deemed clinically important a priori, in order to interpret, validate, and present the meta-regression findings with greater clarity and robustness. The pooled prevlence of NAFLD/MAFLD and the odds ratio (OR) were calculated using a random-effects model. Findings derived from this standard meta-analysis are reported as pooled estimates. Results from meta-regression are reported as regression coefficients (β) with 95% confidence intervals and p-values. Detailed information on the methodology is provided in the supplementary data.Compared to the non-psoriasis control group, psoriasis patients had a significantly higher odds ratio of NAFLD/MAFLD (OR: 2.23, 95% CI: 1.86–2.68). Furthermore, psoriasis patients with comorbid fatty liver disease also exhibited higher Psoriasis Area and Severity Index scores (weighted mean difference: 4.29, 95% CI: 2.54–6.05). Details of the subgroup analyses and meta-regression are provided in the Supplementary File.